Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Resistance Start-Ups: Is Resistance Futile?

This article was originally published in Start Up

Executive Summary

Overcoming drug resistance is a key goal of development--but will anyone fund it?

You may also be interested in...



Eyeing the Hospital Market for Infectious Disease Diagnostics

Hospital-based diagnostics are a tough sell to VCs, partly because big companies dominate the central lab. The area of infectious disease is even more challenging because low-cost culture methods are difficult to displace and novel high-value biomarker content is rare. MRSA screening may be one area where the right factors are coming together to form an opportunity. In some other cases, the same attributes that make rapid tests appealing outside the hospital could help bring them inside.

Eyeing the Hospital Market for Infectious Disease Diagnostics

Hospital-based diagnostics are a tough sell to VCs, partly because big companies dominate the central lab. The area of infectious disease is even more challenging because low-cost culture methods are difficult to displace and novel high-value biomarker content is rare. MRSA screening may be one area where the right factors are coming together to form an opportunity. In some other cases, the same attributes that make rapid tests appealing outside the hospital could help bring them inside.

PhageTech Inc.

PhageTech is mining the genome of phage virus, which infect bacteria, for targets with which to create a new generation of antibiotics.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC089867

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel